Search

Alprenolol

Alprenolol is no longer marketed by AstraZeneca, but may still be available in generic varieties. … One of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.

Sugemalimab

[L32868] Sugemalimab was under investigation in the clinical trial NCT03802591 (A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-esophageal Junction Adenocarcinoma). … [L32868, L32873, L53333] The antibody is produced in Chinese hamster ovary cells by recombinant DNA technology.

Etilefrine

Etilefrine is an adrenergic agonist that appears to interact with beta-1 and some alpha-adrenergic receptors. It has been used as a vasoconstrictor agent.

Pasireotide

It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.

Pinaverium

Pinaverium bromide is the common ingredient in formulations, mostly as oral tablets. … Although it is not a currently approved drug by the FDA, pinaverium is available in over 60 countries including Canada.

Tebentafusp

[L39995] Tebentafusp was subsequently approved for the same indication in the EU in April 2022.[L41675] … [L39995] It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs), a recently developed cancer immunotherapy with a novel mechanism

Gedatolisib

breast cancer without a PIK3CA mutation detected, following progression on or after at least one line of endocrine therapy in the metastatic setting. … [L63796,L63927] The PI3K/AKT/mTOR pathway is a long-standing target in the breast cancer setting, with previously approved agents acting on a single node of it (i.e. PI3Kα, AKT, or mTORC1).

Hyaluronidase (human recombinant)

[L13338] The action of hyaluronidase was first described in 1936, and named in 1939. … [A199047] Hyaluronidase was first used in prescription products in the United States on 5 May 2004.[L13338]

Propentofylline

Terconazole

[A178096] Terconazole was initially approved by the FDA in 1987. … [FDA label] This drug is available in cream and suppository forms and both have demonstrated high levels of safety, efficacy, and tolerability in clinical trials.